Apic Bio
Pioneering gene therapies for rare neurological and liver diseases, targeting Alpha-1 Antitrypsin Deficiency, genetic ALS, and other CNS conditions.
Pioneering gene therapies for rare neurological and liver diseases, targeting Alpha-1 Antitrypsin Deficiency, genetic ALS, and other CNS conditions.
Apic Bio is a biotechnology startup founded in 2017 with a focus on pioneering gene therapies for rare neurological and liver diseases. The company's mission is to address underserved medical conditions, including Alpha-1 Antitrypsin Deficiency (Alpha-1), genetic Amyotrophic Lateral Sclerosis (ALS), and other central nervous system disorders. With their slogan "Pioneering gene therapies for rare neurological and liver diseases," Apic Bio has attracted significant attention and investment in the biotechnology, health care, life sciences, and pharmaceutical industries.
The company has recently received a substantial $42.32M Series A investment on 07 January 2019, demonstrating strong investor confidence in their innovative gene therapy solutions. The funding was provided by ALS Investment and Morningside Venture Investments, further cementing Apic Bio's position as a promising player in the biotechnology and pharmaceutical space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $42.32M | 2 |
|
07 Jan 2019 |
| Venture Round | $10.00M | - | 15 Nov 2018 | |
| Seed Round | $1.00M | 2 | Alpha-1 Foundation, Edward Krapels | 23 Aug 2017 |
No recent news or press coverage available for Apic Bio.
We care about your data, and we'd love to use cookies make your experience better.
